TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer
Status:
Terminated
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of Irinotecan Beads in
combination with intravenous cetuximab versus intravenous irinotecan in combination with
intravenous cetuximab in the treatment of patients with unresectable liver metastases from
colorectal cancer.
Secondary objectives are safety and tolerability of hepatic chemoembolization and the
question if the addition of aprepitant to standard antiemetic prophylaxis in patients treated
by hepatic chemoembolization is safe and will reduce the rate of acute and delayed nausea and
emesis.